D. Priolo

发表

Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study

D. Katsaros, F. Ghezzi, S. Pignata, 2008, BMC Cancer.

ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer

M. Buyse, E. Dreher, Torri, 1998, The Lancet.

Locally advanced non-small cell lung cancer: different strategies for different diseases.

F. Ferraù, D. Priolo, G. Antonelli, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD).

S. Barni, R. Labianca, V. Catalano, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Fludarabine Phosphate as an Active and Well Tolerated Salvage Therapy in an Elderly Heavily Pretreated Hodgkin's Disease Patient: A Case Report

G. Failla, F. Ferraù, R. Bordonaro, 1999, Tumori.

Bevacizumab in the treatment of NSCLC: patient selection and perspectives

J. McCubrey, M. Libra, A. Russo, 2017, Lung Cancer.

Malignant melanoma in elderly patients: biological, surgical and medical issues

J. McCubrey, M. Libra, A. Russo, 2015, Expert review of anticancer therapy.

Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer.

D. Katsaros, S. Pignata, G. Scambia, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.

M. Nicoloso, S. Pignata, G. de Matteis, 2023, The Lancet. Oncology.

Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22)

S. Pignata, V. Canzonieri, C. Casanova, 2022, British Journal of Cancer.

Safety and Activity of the Combination of Pegylated Liposomal Doxorubicin and Weekly Docetaxel in Advanced Breast Cancer

L. Mariani, G. Gasparini, V. Lorusso, 2004, Breast Cancer Research and Treatment.

Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study

V. Adamo, B. Adamo, G. Scambia, 2008, British Journal of Cancer.

Weekly gemcitabine and cisplatin chemotherapy: a well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).

S. Barni, R. Labianca, L. Frontini, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial.

S. Pignata, D. Califano, C. Marchetti, 2023, Gynecologic oncology.

Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22)

S. Pignata, V. Canzonieri, C. Casanova, 2022, British Journal of Cancer.

Malignant melanoma in elderly patients: biological, surgical and medical issues

J. McCubrey, M. Libra, F. Ferraù, 2015, Expert review of anticancer therapy.